The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Latest Features
LATEST ARTICLES
BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
An Early Study Suggests the Flu Shot Could Someday Be Used as Part of an Immunotherapy Regimen in Cancer
A new study describes how the flu vaccine creates an antitumoral response in mouse models of metastatic melanoma that has spread to the lungs.
Risky Business: A New Scoring System for Metastatic Renal Cell Carcinoma
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.
Patient-Reported Outcomes That May Affect Treatment Decisions in Prostate Cancer
Validated PROMs can assist in providing high-quality care and improve a patient’s overall experience.
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Oral Oncology Parity Laws Don’t Make Medications More Affordable
Out-of-pocket spending remains high for many patients with blood cancers who are receiving tyrosine kinase inhibitors and immunomodulatory drugs.
Conference Organizers Can Help Oncologists Distill Practice-Changing Data
A SABCS 2019 session encouraged oncologists to scrutinize whether presentations are practice changing, and included a look at controversial data from KEYNOTE-522.
Patients With Cancer Who Vape Are at Significant Risk for EVALI
A nationwide outbreak of EVALI reports has highlighted the unknowns about one of the most popular forms of inhalation drug use in the US.
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
The cancer field is not immune to the challenges of out-of-network and surprise billing.
PAK4 in Melanoma: Could This Target Extend Immunotherapy’s Reach?
Combining PD-1 blockade with PAK4 inhibitors could boost the number of patients helped by the therapy.
Preclinical Work on Red Blood Cell-Based Therapies in HPV-Positive Solid Tumors Provides Rationale for Clinical Trials in Humans
A microfluidics platform for engineering activated antigen carrier immunotherapies from red blood cells showed promising preliminary results in a mouse model.
How Targeted Therapies Could Actually Promote Cancer Cell Mutability
Research shows how cancer cells can act like bacteria and adapt to increase their chances of survival.
Optimal mCRPC Drug Sequences Emerging
Recent studies provide guidance on which drugs should be used first to obtain the best outcomes.
Want to read more?
Please login or register first to view this content.
